Cargando…

Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C

BACKGROUND: US Food and Drug Administration (FDA) set a rigorous standard for defining patient responders in irritable bowel syndrome-C (IBS-C; i.e., FDA's Responder Endpoint) for regulatory approval. However, this endpoint's utility for health-care practitioners to assess clinical respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lacy, B E, Lembo, A J, MacDougall, J E, Shiff, S J, Kurtz, C B, Currie, M G, Johnston, J M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282394/ https://www.ncbi.nlm.nih.gov/pubmed/24382134 http://dx.doi.org/10.1111/nmo.12264

Ejemplares similares

Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial
por: Lacy, Brian E., et al.
Publicado: (2015)

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation
por: Rao, Satish, et al.
Publicado: (2012)

The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials
por: Chang, L, et al.
Publicado: (2014)

Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Schoenfeld, Philip, et al.
Publicado: (2018)

Linaclotide induces secretion of cGMP from mouse colonic epithelium
por: Tchernychev, Boris, et al.
Publicado: (2013)

Improving the Gastrointestinal Stability of Linaclotide
por: Braga Emidio, Nayara, et al.
Publicado: (2021)

Critical role of down-regulated in adenoma bicarbonate transporter in linaclotide stimulated intestinal bicarbonate secretion
por: Sarthi, Jessica B., et al.
Publicado: (2023)

Randomised clinical trial: linaclotide vs placebo—a study of bi‐directional gut and brain axis
por: Rao, Satish S.C., et al.
Publicado: (2020)

Clarification of Linaclotide Pharmacology Presented in a Recent Clinical Study of Plecanatide
por: Busby, Robert W., et al.
Publicado: (2014)

UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation
por: Yiannakou, Yan, et al.
Publicado: (2018)

Linaclotide for the treatment of refractory lower bowel manifestations of systemic sclerosis
por: Dein, Eric J., et al.
Publicado: (2021)

Linaclotide utilization and potential for off-label use and misuse in three European countries
por: Cid-Ruzafa, Javier, et al.
Publicado: (2022)

Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use
por: Lacy, Brian E, et al.
Publicado: (2017)

Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials
por: Brenner, Darren M., et al.
Publicado: (2023)

Assessment of treatment response in chronic constipation clinical trials
por: Ervin, Claire M, et al.
Publicado: (2014)

The Impact of Stool Consistency on Bowel Movement Satisfaction in Patients With IBS-C or CIC Treated With Linaclotide or Other Medications: Real-World Evidence From the CONTOR Study
por: Taylor, Douglas C.A., et al.
Publicado: (2019)

Review article: linaclotide for the management of irritable bowel syndrome with constipation
por: Layer, P, et al.
Publicado: (2014)

A New Regioselective Synthesis of the Cysteine-Rich Peptide Linaclotide
por: Qiu, Zhonghao, et al.
Publicado: (2023)

Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS
por: Cremonini, F, et al.
Publicado: (2012)

Engineering of an Anti-Inflammatory Peptide Based on the Disulfide-Rich Linaclotide Scaffold
por: Cobos, Claudia, et al.
Publicado: (2018)

Psychometric validation of patient-reported outcome measures assessing chronic constipation
por: Nelson, Lauren M, et al.
Publicado: (2014)

Medical graduate views on statistical learning needs for clinical practice: a comprehensive survey
por: MacDougall, Margaret, et al.
Publicado: (2019)

Characterizing Treatment Non-responders vs. Responders in Completed Alzheimer’s Disease Clinical Trials
por: Wang, Dulin, et al.
Publicado: (2023)

A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa
por: Kang, Sang Bum, et al.
Publicado: (2015)

Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation
por: Lee, Noel, et al.
Publicado: (2012)

Linaclotide-induced electrolyte secretion in human and rat colon: Ussing chamber studies
por: Tchernychev, Boris, et al.
Publicado: (2015)

Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials
por: Lacy, Brian E., et al.
Publicado: (2019)

Defining Responders vs Non-Responders After Total Ankle Arthroplasty
por: Steele, John R., et al.
Publicado: (2019)

Surgical Cases of Interest
por: MacDougall, J. A.
Publicado: (1895)

Surgical Cases of Interest
por: MacDougall, J. A.
Publicado: (1895)

Alexander Blackhall Morison
por: MacDougall, J. A.
Publicado: (1928)

The Late Dr W. G. W. Sanders
por: MacDougall, J. A.
Publicado: (1922)

James Crawford Renton
por: MacDougall, J. A.
Publicado: (1919)

Sir Lauder Brunton
por: MacDougall, J. A.
Publicado: (1916)

William Hall Calvert
por: MacDougall, J. A.
Publicado: (1917)

William Allan Jamieson
por: MacDougall, J. A.
Publicado: (1916)

High‐dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double‐blind, placebo‐controlled study with a long‐term open‐label extension study in Japan
por: Fukudo, Shin, et al.
Publicado: (2018)

Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
por: Chey, William D., et al.
Publicado: (2021)

Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms
por: Serrano-Falcón, Blanca, et al.
Publicado: (2019)

The Proton Pump Inhibitor Non-Responder: A Clinical Conundrum
por: Hussain, Zilla H, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l42ho4k12h9slohpolmmnb9vak